Association of subcutaneous belimumab and long-term antimalarial treatment reduces antiphospholipid antibodies levels in systemic lupus erythematosus: post-hoc analysis of a randomised placebo-controlled trial-comment on: 'Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus' by Chatzidionysiou et al

被引：8

作者：

Bettiol, Alessandra ^{[1
]}

Pregnolato, Francesca ^{[2
]}

Sciascia, Savino ^{[3
,4
]}

Emmi, Giacomo ^{[5
]}

Prisco, Domenico ^{[5
]}

Meroni, Pier Luigi ^{[2
]}

机构：

[1] Univ Florence, Dept Neurosci Psychol Drug Res & Child Hlth NEURO, Florence, Italy

[2] IRCCS, Expt Lab Immunorheumatol, Ist Auxol Italiano, Cusano Milanino, Italy

[3] Osped Torino Nord Emergenza San G Bosco, Dipartimento Malattie Rare Immunol Ematol & Immun, Ctr Ric Immunopatol & Documentaz Malattie Rare, Struttura Complessa Direz Univ Immunol Clin, Turin, Italy

[4] Univ Torino, Turin, Italy

[5] Univ Florence, Dept Expt & Clin Med, I-50134 Florence, Italy

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷 / 08期

关键词：

antibodies; antiphospholipid; biological therapy; lupus erythematosus; systemic; hydroxychloroquine; cardiovascular diseases;

D O I：

10.1136/annrheumdis-2020-218377

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：2

共 6 条

[1] Effect of belimumab treatment on antiphospholipid antibody levels: post-hoc analysis based on two randomised placebo-controlled trials in systemic lupus erythematosus [J].

Chatzidionysiou, Katerina ;

Samoli, Evangelia ;

Sfikakis, Petros P. ;

Tektonidou, Maria G. .

ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 (02) :304-+

[2] Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment [J].

Emmi, Giacomo ;

Bettiol, Alessandra ;

Palterer, Boaz ;

Silvestri, Elena ;

Vitiello, Gianfranco ;

Parronchi, Paola ;

Prisco, Domenico .

AUTOIMMUNITY REVIEWS, 2019, 18 (03) :312-314

[3] Immunoglobulin A anti-phospholipid antibodies in Swedish cases of systemic lupus erythematosus: associations with disease phenotypes, vascular events and damage accrual [J].

Frodlund, M. ;

Vikerfors, A. ;

Grosso, G. ;

Skogh, T. ;

Wettero, J. ;

Elvin, K. ;

Gunnarsson, I. ;

Kastbom, A. ;

Dahlstrom, O. ;

Ronnelid, J. ;

Svenungsson, E. ;

Sjowall, C. .

CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2018, 194 (01) :27-38

[4] Long-term use of hydroxychloroquine reduces antiphospholipid antibodies levels in patients with primary antiphospholipid syndrome [J].

Nuri, Entela ;

Taraborelli, Mara ;

Andreoli, Laura ;

Tonello, Marta ;

Gerosa, Maria ;

Calligaro, Antonia ;

Argolini, Lorenza Maria ;

Kumar, Rajesh ;

Pengo, Vittorio ;

Meroni, Pier Luigi ;

Ruffatti, Amelia ;

Tincani, Angela .

IMMUNOLOGIC RESEARCH, 2017, 65 (01) :17-24

[5] Anticardiolipin and anti-beta 2 glycoprotein-I antibodies disappearance in patients with systemic lupus erythematosus and antiphospholipid syndrome while on belimumab [J].

Sciascia, Savino ;

Rubini, Elena ;

Radin, Massimo ;

Cecchi, Irene ;

Rossi, Daniela ;

Roccatello, Dario .

ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 (11) :1693-+

[6] Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study [J].

Stohl, William ;

Schwarting, Andreas ;

Okada, Masato ;

Scheinberg, Morton ;

Doria, Andrea ;

Hammer, Anne E. ;

Kleoudis, Christi ;

Groark, James ;

Bass, Damon ;

Fox, Norma Lynn ;

Roth, David ;

Gordon, David .

ARTHRITIS & RHEUMATOLOGY, 2017, 69 (05) :1016-1027

← 1 →